# A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

> **NCT02684006** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 886 (actual)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Avelumab (MSB0010718C)
- **DRUG:** Axitinib (AG-013736)
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT02684006
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-23
- **Primary completion:** 2023-08-31
- **Final completion:** 2024-06-26
- **Target enrollment:** 886 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684006, "A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02684006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*